Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S; ML18147 Study Investigators. Bennouna J, et al. Among authors: steffens cc. Lancet Oncol. 2013 Jan;14(1):29-37. doi: 10.1016/S1470-2045(12)70477-1. Epub 2012 Nov 16. Lancet Oncol. 2013. PMID: 23168366 Clinical Trial.
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC, Al-Batran SE, Lange T, Dietrich G, Stoehlmacher J, Tannapfel A, Reinacher-Schick A, Quidde J, Trarbach T, Hinke A, Schmoll HJ, Arnold D. Hegewisch-Becker S, et al. Among authors: steffens cc. Lancet Oncol. 2015 Oct;16(13):1355-69. doi: 10.1016/S1470-2045(15)00042-X. Epub 2015 Sep 8. Lancet Oncol. 2015. PMID: 26361971 Clinical Trial.
Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial.
Coombes RC, Tovey H, Kilburn L, Mansi J, Palmieri C, Bartlett J, Hicks J, Makris A, Evans A, Loibl S, Denkert C, Murray E, Grieve R, Coleman R, Borley A, Schmidt M, Rautenberg B, Kunze CA, Rhein U, Mehta K, Mousa K, Dibble T, Lu XL, von Minckwitz G, Bliss JM; Randomized European Celecoxib Trial (REACT) Trial Management Group and Investigators. Coombes RC, et al. JAMA Oncol. 2021 Sep 1;7(9):1291-1301. doi: 10.1001/jamaoncol.2021.2193. JAMA Oncol. 2021. PMID: 34264305 Free PMC article. Clinical Trial.
Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer.
Stein A, Atanackovic D, Hildebrandt B, Stübs P, Brugger W, Hapke G, Steffens CC, Illerhaus G, Bluemner E, Stöhlmacher J, Bokemeyer C. Stein A, et al. Among authors: steffens cc. Br J Cancer. 2015 Sep 15;113(6):872-7. doi: 10.1038/bjc.2015.299. Epub 2015 Sep 3. Br J Cancer. 2015. PMID: 26335608 Free PMC article. Clinical Trial.
NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim - First Interim Analysis.
Kurbacher CM, Fietz T, Diel IJ, Egert M, Hurtz HJ, Lück A, Weide R, Salat C, Wolff T, Zaiss M, Klare P, Losem C, Illmer T, Weißenborn G, Steffens CC, Schulze M, Tesch H, Oskay-Oezcelik G, Teichmann B, Harde J, Scheuerlein RW. Kurbacher CM, et al. Among authors: steffens cc. Oncol Res Treat. 2015;38(5):221-9. doi: 10.1159/000381631. Epub 2015 May 4. Oncol Res Treat. 2015. PMID: 25966769 Free article.
Observational study of adjuvant therapy with capecitabine in colon cancer.
Steffens CC, Tschechne B, Schardt C, Jacobs G, Valdix AR, Schmidt P, Hansen R, Kröning H, Wohlfarth T, Guggenberger D. Steffens CC, et al. Curr Med Res Opin. 2015 Apr;31(4):731-41. doi: 10.1185/03007995.2015.1014030. Epub 2015 Feb 12. Curr Med Res Opin. 2015. PMID: 25651480
Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study.
Steffens CC, Elender C, Hutzschenreuter U, Dille S, Binninger A, Spring L, Jänicke M, Marschner N; TLK-Group (Tumour Registry Lung Cancer). Steffens CC, et al. Lung Cancer. 2019 Apr;130:216-225. doi: 10.1016/j.lungcan.2019.02.026. Epub 2019 Feb 25. Lung Cancer. 2019. PMID: 30885347 Free article.
Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study.
Dörfel S, Steffens CC, Meyer D, Tesch H, Kruggel L, Frank M, Jänicke M, Marschner N; TMK-Group (Tumour Registry Breast Cancer). Dörfel S, et al. Among authors: steffens cc. Breast Cancer. 2018 May;25(3):275-283. doi: 10.1007/s12282-017-0823-7. Epub 2017 Dec 4. Breast Cancer. 2018. PMID: 29204847 Free PMC article.
Corrigendum to "Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study" [Lung Cancer 130 (2019) (April) 216-225].
Steffens CC, Elender C, Hutzschenreuter U, Dille S, Binninger A, Spring L, Jänicke M, Marschner N; TLK-Group (Tumour Registry Lung Cancer). Steffens CC, et al. Lung Cancer. 2019 Sep;135:236. doi: 10.1016/j.lungcan.2019.07.013. Epub 2019 Jul 22. Lung Cancer. 2019. PMID: 31345567 Free article. No abstract available.
16 results